SECENDS - JNJ

2025

Q4 2 filings

Oct

Q3 2025 Results

Financial data not available in provided excerpt

10-Q

Oct

Q3 Earnings + Orthopaedics Spinoff

Q3 2025 results + separating Orthopaedics business

8-K

Q3 3 filings

Sep

Board Director Elected

John Morikis elected to Board, former Sherwin-Williams CEO

8-K

Jul

Q2 2025 Results

Data unavailable - XBRL metadata only

10-Q

Jul

Q2 2025 Earnings

Q2 ended June 29, 2025 results

8-K

Q2 5 filings

Jun

Director Elected

Daniel Pinto (JPMorgan President) joins board July 1

8-K

Apr

Director Retirement & Annual Meeting

D. Adamczyk retiring May 31, all 11 directors elected

8-K

Apr

Q1 2025 Results

Financial data not available in provided content

10-Q

Apr

Q1 Earnings & Dividend Hike

Q1 2025 results + dividend increased 4.8% to $1.30/share (63rd consecutive year)

8-K

Apr

Bankruptcy Plan Denied

$7B reserve reversal from Red River Talc bankruptcy denial

8-K

Q1 5 filings

Mar

2025 Proxy Statement

Say-on-pay: 90%, 62 consecutive dividend increases

DEF 14A

Feb

Euro Bond Offering

€4B notes across 5 tranches, 2.7%-3.7% coupons, 2029-2055 maturities

8-K

Feb

Debt Offering

$5B notes issued, rates 4.5%-5.0%

8-K

Feb

FY2024 Results

Unable to extract revenue and EPS - financial data not readable in XBRL format

📌 Kenvue consumer products business IPO and spinoff completed in 2023, focusing JNJ on pharma and medtech segments

10-K

Jan

Q4 2024 Earnings

Q4 and full year 2024 results announced

8-K

2024

Q4 2 filings

Oct

Q3 2024 Results

Financial data not available in provided content

10-Q

Oct

Q3 Earnings

Q3 2024 results for period ended Sept 29

8-K

Q3 5 filings

Sep

Talc Litigation Bankruptcy Settlement

$8B settlement via subsidiary Chapter 11 filing

8-K

Sep

Director Retirement

D.S. Davis retired as Director, Audit Committee Chair transition to D. Adamczyk

8-K

Aug

CHRO Retirement

Peter M. Fasolo retiring October 1, 2024

8-K

Jul

Q2 2024 Results

Unable to extract revenue and EPS data from provided XBRL content

10-Q

Jul

Q2 Earnings

Q2 2024 results for period ended June 30, 2024

8-K

Q2 6 filings

May

Multi-Tranche Debt Offering

$6B total: $4B USD notes (4.8-5.25%) + €2.5B EUR notes (3.2-3.55%)

8-K

May

Completed Kenvue Divestiture

Exchanged remaining 182M Kenvue shares for $3.6B commercial paper

8-K

May

Q1 2024 Results

Financial figures not clearly extractable from provided XBRL structure

10-Q

May

Q1 Earnings + $6.5B Talc Settlement

EPS revised down from $2.20 to $1.34 due to $2.7B incremental talc charge

8-K

Apr

Annual Shareholder Meeting & Bylaws Amendment

All 13 directors elected, bylaws updated for special meetings and proxy rules

8-K

Apr

Q1 Earnings & Dividend Increase

Q1 2024 results released, dividend raised 4.2% to $1.24/share (62nd consecutive year)

8-K

Q1 2 filings

Mar

2024 Proxy Statement

Say-on-pay: 93.2%, Kenvue separation: $13.2B proceeds

DEF 14A

Feb

FY2023 2023 Results

Unable to extract revenue and EPS from provided XBRL data

📌 Kenvue IPO completed on May 8, 2023 - J&J spun off consumer products division

10-K